Induction of adrenal suppression by megestrol acetate in patients with AIDS
- PMID: 7741369
- DOI: 10.7326/0003-4819-122-11-199506010-00006
Induction of adrenal suppression by megestrol acetate in patients with AIDS
Abstract
Objective: To investigate the development of secondary adrenal suppression in a patient with the acquired immunodeficiency syndrome (AIDS) who was receiving megestrol acetate.
Design and patients: Case report of one patient abruptly withdrawn from long-term therapy with megestrol acetate; prospective study of four patients with AIDS who were starting therapy with megestrol acetate for cachexia.
Setting: Outpatient clinic of a university hospital.
Interventions: Study patients received megestrol acetate, 80 mg three times daily.
Measurements: Study patients had cosyntropin-stimulation testing and oral glucose tolerance testing before and after starting therapy with megestrol acetate.
Results: The patient described in the case report developed symptoms of adrenal insufficiency after withdrawal of megestrol acetate after 4 years of treatment. His basal cortisol and adrenocorticotropic hormone (ACTH) levels were low. He showed an abnormally diminished response to a short cosyntropin-stimulation test but did respond to a 3-day cosyntropin-stimulation test. The morning cortisol levels of the study patients decreased significantly (from 11.0 +/- 1.8 micrograms/dL to 1.5 +/- 0.9 micrograms/dL; P < 0.01), and the ACTH levels of these patients decreased to below normal (from 16.6 +/- 5.5 pg/mL to 6.3 +/- 3.3 pg/mL; P = 0.02) during treatment with megestrol acetate. Cortisol levels after administration of cosyntropin decreased significantly (from 27.3 +/- 3.3 pg/mL to 9.3 +/- 6.3 pg/mL; P = 0.01) during treatment with megestrol acetate. The results of oral glucose tolerance testing in two patients were consistent with the development of insulin resistance, and daily insulin requirements increased 10-fold in a patient who had preexisting diabetes.
Conclusions: Prolonged administration of megestrol acetate can induce clinically significant secondary adrenal suppression, and abrupt withdrawal of megestrol acetate after prolonged administration can cause adrenal insufficiency.
Comment in
-
Induction of adrenal suppression by megestrol acetate.Ann Intern Med. 1996 Mar 15;124(6):613; author reply 614. doi: 10.7326/0003-4819-124-6-199603150-00017. Ann Intern Med. 1996. PMID: 8597329 No abstract available.
-
Induction of adrenal suppression by megestrol acetate.Ann Intern Med. 1996 Mar 15;124(6):613; author reply 614. doi: 10.7326/0003-4819-124-6-199603150-00016. Ann Intern Med. 1996. PMID: 8597330 No abstract available.
-
Induction of adrenal suppression by megestrol acetate.Ann Intern Med. 1996 Mar 15;124(6):613-4. doi: 10.7326/0003-4819-124-6-199603150-00018. Ann Intern Med. 1996. PMID: 8597331 No abstract available.
Similar articles
-
Megestrol for AIDS-related anorexia.Ann Intern Med. 1995 Jun 1;122(11):880; author reply 881. doi: 10.7326/0003-4819-122-11-199506010-00017. Ann Intern Med. 1995. PMID: 7741378 No abstract available.
-
Megestrol acetate in patients with AIDS-related cachexia.Ann Intern Med. 1994 Sep 15;121(6):393-9. doi: 10.7326/0003-4819-121-6-199409150-00001. Ann Intern Med. 1994. PMID: 7794302 Clinical Trial.
-
Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia.Ann Intern Med. 1992 Jan 1;116(1):53-4. doi: 10.7326/0003-4819-116-1-53. Ann Intern Med. 1992. PMID: 1727096 No abstract available.
-
Treatment of anorexia with megestrol acetate.Nutr Clin Pract. 1993 Jun;8(3):115-8. doi: 10.1177/0115426593008003115. Nutr Clin Pract. 1993. PMID: 8289758 Review.
-
Megestrol acetate NCD oral suspension -- Par Pharmaceutical: megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2.Drugs R D. 2007;8(4):251-4. doi: 10.2165/00126839-200708040-00005. Drugs R D. 2007. Corrected and republished in: Drugs R D. 2007;8(6):403-6. doi: 10.2165/00126839-200708060-00009 PMID: 17596111 Corrected and republished. Review.
Cited by
-
Megestrol Acetate for Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer: An Old Answer for a New Problem.Case Rep Oncol. 2022 Mar 29;15(1):312-317. doi: 10.1159/000522086. eCollection 2022 Jan-Apr. Case Rep Oncol. 2022. PMID: 35529294 Free PMC article.
-
Megestrol acetate drives endometrial carcinoma cell senescence via interacting with progesterone receptor B/FOXO1 axis.Exp Biol Med (Maywood). 2021 Nov;246(21):2307-2316. doi: 10.1177/15353702211026566. Epub 2021 Jul 7. Exp Biol Med (Maywood). 2021. PMID: 34233525 Free PMC article.
-
Megestrol Acetate-Induced Symptomatic Hypogonadism in a Male Patient.Case Rep Endocrinol. 2018 Jul 18;2018:7048610. doi: 10.1155/2018/7048610. eCollection 2018. Case Rep Endocrinol. 2018. PMID: 30112227 Free PMC article.
-
Megace Mystery: A Case of Central Adrenal Insufficiency.Case Rep Endocrinol. 2015;2015:147265. doi: 10.1155/2015/147265. Epub 2015 Dec 6. Case Rep Endocrinol. 2015. PMID: 26770843 Free PMC article.
-
Endocrine sequelae of cancer and cancer treatments.J Cancer Surviv. 2007 Dec;1(4):261-74. doi: 10.1007/s11764-007-0038-6. Epub 2007 Nov 20. J Cancer Surviv. 2007. PMID: 18648961
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical